Ismail M. Meraz
YOU?
Author Swipe
View article: Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1 regulator of cap-dependent translation
Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1 regulator of cap-dependent translation Open
Sotorasib (AMG510) and adagrasib (MRTX849) have shown significant efficacy in KRASG12C mutant NSCLC, but acquired resistance occurs within 6–12 months. While some resistance arises from new mutations, over half of the resistant cases lack …
View article: Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1 regulator of cap-dependent translation
Acquired resistance to sotorasib in KRASG12C mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1 regulator of cap-dependent translation Open
Sotorasib (AMG510) and adagrasib (MRTX849) have shown significant efficacy in KRASG12C mutant NSCLC, but acquired resistance occurs within 6–12 months. While some resistance arises from new mutations, over half of the resistant cases lack …
View article: Supplementary Data from Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy
Supplementary Data from Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy Open
Supplementary results
View article: Data from Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy
Data from Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy Open
Cancer genomic studies have identified frequent alterations in genes encoding components of the SWI/SNF chromatin remodeling complex, including SMARCA4 and ARID1A. Importantly, clinical reports indicate that SMARCA4-mutant lung cancers res…
View article: Acquired resistance to sotorasib in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1, a regulator of cap-dependent translation
Acquired resistance to sotorasib in <i>KRAS</i> <sup> <i>G12C</i> </sup> mutant NSCLC is vulnerable to PI3K-mTOR pathway inhibition mediated by 4E-BP1, a regulator of cap-dependent translation Open
Sotorasib and adagrasib have shown significant efficacy in KRAS G12C mutant NSCLC; however, acquired resistance (AR) occurs within 6–12 months. While some resistance arises from new mutations, over half of the resistant cases lack identifi…
View article: Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy
Mutation of SMARCA4 Induces Cancer Cell–Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy Open
Cancer genomic studies have identified frequent alterations in genes encoding components of the SWI/SNF chromatin remodeling complex, including SMARCA4 and ARID1A. Importantly, clinical reports indicate that SMARCA4-mutant lung cancers res…
View article: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model Open
Expression of NPRL2/TUSC4 , a tumor-suppressor gene, is reduced in many cancers including NSCLC. Restoration of NPRL2 induces DNA damage, apoptosis, and cell-cycle arrest. We investigated NPRL2 antitumor immune responses in aPD1 R / KRAS/S…
View article: Correction: Multivalent Presentation of MPL by Porous Silicon Microparticles Favors T Helper 1 Polarization Enhancing the Anti-Tumor Efficacy of Doxorubicin Nanoliposomes
Correction: Multivalent Presentation of MPL by Porous Silicon Microparticles Favors T Helper 1 Polarization Enhancing the Anti-Tumor Efficacy of Doxorubicin Nanoliposomes Open
[This corrects the article DOI: 10.1371/journal.pone.0094703.].
View article: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model Open
NPRL2/TUSC4 is a tumor suppressor gene whose expression is reduced in many cancers including NSCLC. Restoration of NPRL2 expression in cancer cells induces DNA damage which leads to cell cycle arrest and apoptosis. We investigated the anti…
View article: Author response: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
Author response: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model Open
NPRL2/TUSC4 is a tumor suppressor gene whose expression is reduced in many cancers including NSCLC. Restoration of NPRL2 expression in cancer cells induces DNA damage which leads to cell cycle arrest and apoptosis. We investigated the anti…
View article: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model Open
Expression of NPRL2/TUSC4 , a tumor-suppressor gene, is reduced in many cancers including NSCLC. Restoration of NPRL2 induces DNA damage, apoptosis, and cell-cycle arrest. We investigated NPRL2 antitumor immune responses in aPD1 R / KRAS/S…
View article: <i>SMARCA4</i>mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy
<i>SMARCA4</i>mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy Open
Cancer genomic studies have identified frequent alterations in components of the SWI/SNF (SWItch/Sucrose Non- Fermenting) chromatin remodeling complex including SMARCA4 and ARID1A . Importantly, clinical reports indicate that SMARCA4 -muta…
View article: NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model
NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic non-small cell lung cancer (NSCLC) in a humanized mouse model Open
NPRL2/TUSC4 is a tumor suppressor gene whose expression is reduced in many cancers including NSCLC. Restoration of NPRL2 expression in cancer cells induces DNA damage which leads to cell cycle arrest and apoptosis. We investigated the anti…
View article: Supplementary Figures from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Supplementary Figures from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses Open
Figure S1-S7
View article: Supplementary Figures from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Supplementary Figures from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses Open
Figure S1-S7
View article: Supplementary Figure Legends from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Supplementary Figure Legends from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses Open
Legends to Figures S1-S7
View article: Data from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Data from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses Open
Human tumor xenograft models do not replicate the human immune system and tumor microenvironment. We developed an improved humanized mouse model, derived from fresh cord blood CD34+ stem cells (CD34+ HSC), and combined it with lung cancer …
View article: Data from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Data from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses Open
Human tumor xenograft models do not replicate the human immune system and tumor microenvironment. We developed an improved humanized mouse model, derived from fresh cord blood CD34+ stem cells (CD34+ HSC), and combined it with lung cancer …
View article: Supplementary Figure Legends from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses
Supplementary Figure Legends from An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses Open
Legends to Figures S1-S7
View article: Supplementary Figure Legends from Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells
Supplementary Figure Legends from Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells Open
Figure Legends for Supplementary Figures S1-S4.
View article: Supplementary Figure Legends from Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells
Supplementary Figure Legends from Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells Open
Figure Legends for Supplementary Figures S1-S4.
View article: Data from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i>-Mutant Mouse Lung Cancer Models
Data from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i>-Mutant Mouse Lung Cancer Models Open
Expression of the multikinase inhibitor encoded by the tumor suppressor gene TUSC2 (also known as FUS1) is lost or decreased in non–small cell lung carcinoma (NSCLC). TUSC2 delivered systemically by nanovesicles has mediated tumor regressi…
View article: Supplemental Figures from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i>-Mutant Mouse Lung Cancer Models
Supplemental Figures from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i>-Mutant Mouse Lung Cancer Models Open
Supplemental Figures 1-4
View article: Supplemental Figure Legends from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i>-Mutant Mouse Lung Cancer Models
Supplemental Figure Legends from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i>-Mutant Mouse Lung Cancer Models Open
S1. Gating strategy of peripheral blood leukocytes and splenocytes was shown to determine immune subpopulations for multi-color flow cytometry assay. S2. Effect of NK depletion antibody (NK1.1) on other immune cells. S3. Effect of CD8 T de…
View article: Supplemental Figures from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i>-Mutant Mouse Lung Cancer Models
Supplemental Figures from TUSC2 Immunogene Therapy Synergizes with Anti–PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic <i>Kras</i>-Mutant Mouse Lung Cancer Models Open
Supplemental Figures 1-4